PharmAthene Reports Year-End 2007 Financi... ( ANNAPOLIS Md. March 31 /- PharmAt...)

PharmAthene Reports Year-End 2007 Financial Results

Date:3/31/2008

ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial results for the year ended December 31, 2007.

David P. Wright, President and Chief Executive Officer commented, "In 2007 we continued to advance both our corporate and product development objectives and achieved a number of important milestones which included, obtaining additional contract and appropriations funding for Valortim(TM) and Protexia(R) and generating promising new data in each of these programs. We also completed a merger with Healthcare Acquisition Corp. which provided a stronger financial foundation with enhanced access to capital with which to pursue our business objectives. Our goal was to use these resources to accelerate our growth, which was recently demonstrated by the execution of an agreement for the acquisition of Avecia's biodefense vaccines."

Current and Full Year 2007 Highlights

In addition to the recently announced sale and purchase agreement signed with Avecia, PharmAthene also demonstrated significant achievements in 2007, including:

-- Completing a merger with Healthcare Acquisition Corp. and building a

stronger financial foundation for the Company. As a result of the

merger PharmAthene obtained approximately $57.9 million in capital.

-- Receiving a contract for up to $13.9 million from the National

Institutes of Health to support the development of Valortim(TM) for use

as an anti-toxin therapeutic to prevent and treat inhalational anthrax

infection.

-- Obtaining up to an additional $2.4 million in funding for Valorti
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008

Post Your Comments:

PharmAthene Reports Year-End 2007 Financi...( ANNAPOLIS Md. March 31 /- PharmAt...)